ADMA Biologics, Inc. (NASDAQ:ADMA) reported better-than-expected first-quarter financial results and issued strong revenue guidance on Thursday. ADMA Biologics posted GAAP earnings of 8 cents per share, beating market estimates of 5 cents per share. The company's quarterly sales came in at $81.875 million versus expectations of $77.275 million, according to data from Benzinga Pro. “ADMA’s commercial success continues to unfold, and during the first quarter of 2024, we surpassed our financial expectations and delivered compounding earnings growth. The versatility and strength of our ...